Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2026)

Arcus Biosciences' Non-Current Assets history runs 10 years deep, the most recent figure standing at $153.0 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 9.47% year-over-year to $153.0 million in Q1 2026; TTM through Mar 2026 was $531.0 million, a 18.81% decrease from a year earlier, with the FY2025 full-year figure at $132.0 million, down 1.49% from the prior year.
• Non-Current Assets advanced to $153.0 million in Q1 2026 per RCUS's latest filing, from $132.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $309.0 million in Q3 2023 and bottomed at $117.0 million in Q3 2025.
• The 5-year median for Non-Current Assets is $233.0 million (2022), against an average of $207.1 million.
• Across the five-year window, Non-Current Assets soared 199.41% in 2022 and sank 49.24% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $233.0 million in 2022, then grew by 13.3% to $264.0 million in 2023, then sank by 49.24% to $134.0 million in 2024, then declined by 1.49% to $132.0 million in 2025, then increased by 15.91% to $153.0 million in 2026.
• Per Business Quant, the three latest RCUS Non-Current Assets figures stand at $153.0 million (Q1 2026), $132.0 million (Q4 2025), and $117.0 million (Q3 2025).